Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Challenges in Initiating Venetoclax-Based Treatment for Patients With CLL

12/11/2024

John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).

John M. Burke, MD, Rocky...

12/11/2024

Journal of Clinical Pathways

Videos

Factors Impacting the Development and Selection of Targeted Therapies for Patients With CLL

12/04/2024

Matthew S. Davids , MD, MMSc;

Matthew S. Davids, MD, speaks about the latest targeted therapies for treating CLL, the challenges in developing these treatments, and how they are being used in the community oncology setting.

Matthew S. Davids, MD, speaks...

12/04/2024

Journal of Clinical Pathways

Videos

Chronic Lymphocytic Leukemia Treatment Trends in Community Oncology Settings

11/26/2024

Danielle M. Brander , MD;

Danielle Brander, MD, highlights current trends in the community oncology setting for treating chronic lymphocytic leukemia (CLL) and how clinical pathways can assist oncologists with decision making for frontline therapy in CLL.

Danielle Brander, MD, highlights...

11/26/2024

Journal of Clinical Pathways

Videos

Insights on BTK Inhibitors as Frontline Treatment for Chronic Lymphocytic Leukemia

11/22/2024

;

Danielle Brander, MD, discusses the latest National Comprehensive Cancer Network guidelines for chronic lymphocytic leukemia (CLL) and the efficacy of BTK inhibitors as monotherapy in the frontline treatment of CLL.

Danielle Brander, MD, discusses...

11/22/2024

Journal of Clinical Pathways

Videos

Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up

11/08/2024

;

Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...

Kerry Rogers, MD, provides a...

11/08/2024

Journal of Clinical Pathways

Videos

Exciting Developments in Chronic Lymphocytic Leukemia Treatment Research

08/28/2024

Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.

Matthew Davids, MD, discusses...

08/28/2024

Oncology

Videos

Treatment Options for Chronic Lymphocytic Leukemia Beyond Chemotherapy

08/26/2024

Matthew Cortese , MD, MPH;

Matthew Cortese, MD, discusses recent updates in the National Comprehensive Cancer Network guidelines for the treatment of chronic lymphocytic leukemia (CLL) and ongoing clinical trials in this space.

Matthew Cortese, MD, discusses...

08/26/2024

Journal of Clinical Pathways

Videos

Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia

08/14/2024

Farrukh T. Awan , MD;

Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).

Farrukh Awan, MD, highlights...

08/14/2024

Journal of Clinical Pathways

Videos

Exploring New Therapies on the Horizon for Patients With R/R Chronic Lymphocytic Leukemia

08/09/2024

Nirav R. Shah , MD;

Nirav Shah, MD, shares insights into the research on exciting new therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK degraders and cell therapies.

Nirav Shah, MD, shares insights...

08/09/2024

Oncology

Videos

Chronic Lymphocytic Leukemia Treatment Updates

07/31/2024

Farrukh T. Awan , MD;

Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.

Farrukh Awan, MD, discusses some...

07/31/2024

Journal of Clinical Pathways

Current Issue

December 2024

Volume 10

Issue 6

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Interview

Challenges in Initiating Venetoclax-Based Treatment for Patients With CLL

12/11/2024

John M. Burke , MD;

John M. Burke, MD, Rocky...

12/11/2024

Journal of Clinical Pathways

Videos

Factors Impacting the Development and Selection of Targeted Therapies for Patients With CLL

12/04/2024

Matthew S. Davids , MD, MMSc;

Matthew S. Davids, MD, speaks about the latest targeted therapies for treating CLL, the challenges in developing these treatments, and how they are being used in the community oncology setting.

Matthew S. Davids, MD, speaks...

12/04/2024

Journal of Clinical Pathways